Innovation and Alfasigma Ink Pact to Develop and Commercialize Brilacidin for Types of IBD

Innovation and Alfasigma Ink Pact to Develop and Commercialize Brilacidin for Types of IBD
Innovation Pharmaceuticals now has a global licensing agreement with Alfasigma for the development and commercialization of the therapy  Brilacidin for treating ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), types of inflammatory bowel disease (IBD). Innovation’s lead candidate, Brilacidin is a synthetic small molecule that structurally resembles some of the proteins the body produces to fend off bacteria and other microbial invaders. That’s why it’s being studied as an antibiotic. But, Brilacidin also has immunomodulatory properties — meaning it can lower inflammation and even promote wound-healing — making it a prospective therapy for UP/UPS, a type of ulcerative colitis. Data from a proof-of-concept clinical trial in UP/UPS, in which Brilacidin was administered via enema, showed the treatment’s safety and effectiveness. Half of the patients (six) treated with the compound went into clinical remission and two went into partial remission. Last November, Innovation presented a scientific poster at the inaugural IBD Innovate 2018 conference, hosted by the Crohn’s & Colitis Foundation. ”This licensing agreement with Alfasigma is a major milestone for the company,” said a press release statement by Arthur P. Bertolino, MD, PhD,  Innovation’s president and chief medical officer. “We are confident that Brilacidin for UP/UPS is in good hands, as Alfasigma works to potentially commercialize the drug. At the same time, we’re excited to be underway with our own Brilacidin oral formulation efforts to treat more extensive forms of IBD.” Under terms of the pact, Innovation will receive more than $24 million in an initial sum and milestone-based payments, plus 6% of net sales. The agreement also calls for right of first refus
Subscribe or to access all post and page content.